Drugs / OCU500
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07536308 | May 2026 → Apr 2027 expected | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-01-27 | Ocugen | Regulatory Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19 ocugen.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has reviewed the Company’s Investigational New Drug (IND) application and it is in effect. |
All press releases naming this drug 2 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OCU500 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07536308 ↗ |
| Modality | Vaccine | “OCU500 is a monovalent, replication-defective, chimpanzee adenovirus (ChAd36)-vectored COVID-19 vaccine” NCT07536308 ↗ |
| Route | Inhaled | “administered via inhalation” NCT07536308 ↗ |
| Route | Intranasal | “administered via inhalation” NCT07536308 ↗ |